Can I initiate divalproex (valproate) for mood stabilization in a patient with seizures who is currently taking levetiracetam (Keppra) 750 mg twice daily?

Yes, you can safely initiate divalproex for mood stabilization in this patient already taking levetiracetam (Keppra) 750 mg BID for seizures.

There is no clinically significant pharmacokinetic interaction between divalproex (valproate) and levetiracetam, making this combination safe and appropriate for dual indications of seizure control and mood stabilization. 1, 2

Evidence Supporting This Combination

No Drug-Drug Interaction

• Levetiracetam does not affect valproate metabolism: In vitro and in vivo studies demonstrate that levetiracetam (1500 mg twice daily) does not alter valproate pharmacokinetics in healthy volunteers 2
• Valproate does not affect levetiracetam clearance: Valproate 500 mg twice daily does not modify levetiracetam absorption, plasma clearance, or urinary excretion 1, 2
• No dose adjustment needed: The FDA label for Keppra explicitly states that valproate does not influence levetiracetam pharmacokinetics, and no dose adjustment is required when these drugs are co-administered 1

Clinical Efficacy Data

Multiple studies support the combined use of these medications:

• Pediatric epilepsy: Meta-analysis of 617 patients showed sodium valproate combined with levetiracetam significantly improved therapeutic outcomes (RR=1.24,95% CI: 1.16-1.33) and reduced adverse drug reactions (RR=0.54,95% CI: 0.37-0.79) compared to valproate alone 3
• Status epilepticus: Both medications show comparable efficacy when used as second-line agents, with valproate achieving 68% seizure cessation and levetiracetam 73% in refractory cases 4
• Mood stabilization: Valproate demonstrates clear dose-response for mood stabilization, with effectiveness at doses ranging from 125-500 mg daily for milder bipolar spectrum disorders 5

Practical Implementation Strategy

Starting Divalproex

1. Initial dosing: Begin with 250-500 mg daily, divided into 2 doses
2. Titration: Increase by 250 mg every 3-5 days based on clinical response
3. Target dose: 750-2000 mg daily for mood stabilization (lower end for milder symptoms, higher for more severe bipolar symptoms)
4. Therapeutic monitoring: Target valproate level 50-100 mcg/mL for mood stabilization

Baseline Monitoring (Before Starting Divalproex)

• Complete blood count (CBC)
• Liver function tests (AST, ALT, bilirubin)
• Pregnancy test in females of childbearing age
• Baseline weight and BMI

Ongoing Monitoring

• Repeat CBC and liver function tests at 1 month, then every 3-6 months 6
• Monitor for symptoms of hepatotoxicity (nausea, vomiting, lethargy, jaundice)
• Monitor for hematologic abnormalities (bruising, bleeding)
• Track weight monthly for first 3 months, then quarterly

Critical Caveats and Warnings

Avoid Valproate If:

• Female of childbearing potential: Valproate carries significant teratogenic risk and should be avoided if possible in women who could become pregnant 7. Consider alternative mood stabilizers (lithium, lamotrigine, or potentially higher-dose levetiracetam) in this population
• Polycystic ovary disease risk: Be aware of concerns regarding valproate and development of PCOS in females 6
• Pregnancy: Valproate should be avoided; folic acid supplementation is mandatory if use is unavoidable 7

Monitor for Rare but Serious Interaction

While pharmacokinetic interactions are absent, one case report describes levetiracetam-induced encephalopathy when added to valproate, manifesting as increased seizure frequency, cognitive impairment, and EEG slowing 8. This appears to be a rare pharmacodynamic interaction. Monitor for:

• Increased seizure frequency
• Cognitive decline or confusion
• Excessive sedation
• Worsening EEG findings

If these occur, consider reducing levetiracetam dose or discontinuing one agent.

Seizure Control Considerations

• Continue current levetiracetam: The patient's seizures are presumably controlled on Keppra 750 mg BID; maintain this dose 1
• Dual benefit potential: Both medications have antiepileptic properties, potentially providing additive seizure protection 7, 3
• Enzyme-inducing AEDs: Unlike phenytoin, phenobarbital, or carbamazepine, neither valproate nor levetiracetam significantly induces hepatic enzymes, avoiding problematic drug interactions 9, 1

Alternative Consideration

If mood stabilization is the primary goal and seizures are well-controlled, consider whether levetiracetam dose optimization might provide mood-stabilizing effects before adding valproate. One case report demonstrated levetiracetam alone provided both seizure control and mood stabilization after multiple other agents failed 10. However, evidence for levetiracetam as a primary mood stabilizer remains limited compared to valproate's established efficacy.

Bottom line: Proceed with adding divalproex while maintaining current levetiracetam, but avoid this combination in women of childbearing potential unless no alternatives exist and adequate contraception is ensured.